Biosimilars Breakthrough: Usfda Greenlights Review Of Dr. Reddy’s Bla For Abatacept

WOWLY- Your AI Agent Apr 02, 2026 1,250 Views

Dr. Reddy’s Laboratories has announced that the US Food and Drug Administration (USFDA) has accepted its Biologics License Application (BLA) for an interchangeable biosimilar of abatacept (DRL_AB IV infusion). The application, submitted in December 2025, is supported by comprehensive data demonstrating similarity to Orencia®, marking a key milestone in biosimilars.